Figure 2From: Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasPharmacokinetic parameters for individual patients on treatment day 5. (a) Dose versus peak plasma concentration, Cmax. (b) Dose versus area under the concentration–time curve (AUC).Back to article page